In this issue:
Cost-effectiveness of first- versus second-line use of daratumumab
Daratumumab combinations induce high rates of durable MRD-negativity in RR disease
Use of front-line carfilzomib in high-risk disease mitigates poor prognosis
The burden in caregivers of MM patients undergoing outpatient ASCT
ReLApsE: salvage transplant versus continuous novel agent treatment
Does lenalidomide maintenance impact the efficacy of second-line chemotherapy?
Genomic analysis identifies double-hit group of ultra-high-risk patients
Longer telomere lengths increase the risk of MM
Skeletal survey not appropriate to identify myeloma-related bone lytic lesions
Microenvironment immune reconstitution patterns correlate with outcomes after transplant
Please login below to download this issue (PDF)